Characteristics of Studies on Prenatal Asthma Medication and Neurodevelopment

Eight studies with 3,867,170 participants were included in a systematic review and meta-analysis investigating prenatal asthma medication exposure. The dataset, created by Lama A. Shakhshir and last updated in June 2026, compiles characteristics from cohort and case-control studies published between 2003 and 2025. A meta-analysis of three studies suggested an association between beta-2-adrenergic agonist exposure and autism spectrum disorder.

Use Cases

• Replicating meta-analysis results based on the aggregated study characteristics.
• Assessing study design and quality for systematic reviews on prenatal medication safety.
• Identifying research gaps in the association between specific asthma medications and outcomes like ADHD or ASD.

Strengths

• Includes data from eight studies with a total of 3,867,170 participants.
• Follows PRISMA guidelines and the PECO framework for systematic review methodology.
• Meta-analysis results for ASD are reported with specific adjusted odds ratios and confidence intervals.

Limitations

• The dataset is very small at 9.5 KB, indicating limited scope and detail.
• Column-level documentation is absent; field semantics must be inferred after download.
• The description notes limitations of the included studies, such as residual confounding and exposure misclassification.

Provenance

Source

figshare

Collection Method

Systematic review of PubMed, Medline, and Embase databases.

Time Range

Studies published between January 2003 and November 2025.

Freshness

Last updated 2026-06-01 17:50:53